Physician profile
David Goebel
NPI 1306845474
$6,983.21
in general payments reported to CMS, 2019-2025
42 companies · $380 in 2025
The $380 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,064 · 2020: $1,019 · 2021: $977 · 2022: $922 · 2023: $914 · 2024: $707 · 2025: $380.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,797 · Education: $205.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,796.83 |
| Education | $204.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $1,142.37 | 2019-2023 | Opdivo, Opdualag |
| Astrazeneca Pharmaceuticals LP | $863.59 | 2019-2025 | Lynparza |
| Janssen Biotech, INC. | $798.08 | 2019-2025 | Darzalex, Tecvayli, Talvey |
| Celgene Corporation | $493.70 | 2019-2023 | Opdualag |
| Merck Sharp & Dohme LLC | $448.94 | 2019-2024 | Keytruda, Lynparza |
| Novartis Pharmaceuticals Corporation | $380.41 | 2019-2025 | |
| Amgen INC. | $355.31 | 2019-2023 | Lumakras |
| Beigene USA, INC. | $278.03 | 2020-2024 | Brukinsa |
| Jazz Pharmaceuticals INC. | $251.26 | 2019-2022 | |
| Pfizer INC. | $243.32 | 2019-2025 | |
| Gilead Sciences, INC. | $175.76 | 2023-2025 | Trodelvy |
| Genzyme Corporation | $174.15 | 2019-2023 | |
| Genentech USA, INC. | $155.84 | 2019-2020 | |
| Agios Pharmaceuticals, INC. | $118.54 | 2019 | |
| Daiichi Sankyo INC. | $115.18 | 2022-2023 | Injectafer |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Goebel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.